![Frank Neumann](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Profile
Frank Neumann formerly worked at bluebird bio, Inc., as Vice President & Head-Oncology Clinical Research, Verastem, Inc., as Chief Medical Officer in 2021, and Kite Pharma, Inc., as Head-Clinical Development from 2021 to 2024.
Dr. Neumann received his doctorate degree from Heinrich-Heine-Universität Düsseldorf.
Former positions of Frank Neumann
| Companies | Position | End |
|---|---|---|
| KITE PHARMA INC | Corporate Officer/Principal | 30/04/2024 |
| VERASTEM, INC. | Chief Tech/Sci/R&D Officer | 19/01/2021 |
| GENETIX BIOTHERAPEUTICS, INC. | Corporate Officer/Principal | - |
Training of Frank Neumann
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
14
1st degree connections
5
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 5 |
|---|---|
bluebird bio, Inc.
 bluebird bio, Inc. BiotechnologyHealth Technology Develops genetic therapies based on blood stem cells | Health Technology |
University of Bonn
 University of Bonn Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Heinrich-Heine-Universität Düsseldorf
 Heinrich-Heine-Universität Düsseldorf Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Verastem, Inc.
 Verastem, Inc. BiotechnologyHealth Technology Discovers and develops drugs | Health Technology |
Kite Pharma, Inc.
 Kite Pharma, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical stage biotechnology company which engages in the development of novel cancer immunotherapeutic products | Health Technology |
- Stock Market
- Insiders
- Frank Neumann
